SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Schizophrenic Disorder Clinical Trial

Official title:
A 6-week, Multicenter, Double-blind, Double-dummy, Randomized Comparison of the Efficacy & Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

Status Completed

Clinical Trial Summary

The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00206115
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 3
Start date	November 2004
Completion date	December 2005

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03010865` - Sodium Butyrate For Improving Cognitive Function In Schizophrenia	Phase 2/Phase 3
Completed	`NCT01852331` - Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia	Phase 2
Completed	`NCT00018837` - Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome	N/A